Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An announcement from FibroGen ( (FGEN) ) is now available.
FibroGen has appointed David DeLucia as Chief Financial Officer, succeeding Juan Graham. DeLucia brings extensive financial leadership within the life sciences industry to the role, having previously served as Vice President of Financial Planning & Analysis at FibroGen. His appointment comes as the company aims to advance its strategic vision and build on the performance of products like FG-3246 and roxadustat. This leadership change is expected to bolster the company’s financial strategy and execution as it continues its focus on developing therapies for cancer and related conditions.
More about FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies in cancer biology. It is known for products like Roxadustat, approved for anemia treatment in chronic kidney disease patients across various regions, and FG-3246, an antibody-drug conjugate for prostate cancer treatment. The company also develops immuno-oncology products for solid tumors.
YTD Price Performance: -62.53%
Average Trading Volume: 1,166,375
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $33.55M
Learn more about FGEN stock on TipRanks’ Stock Analysis page.
